Last reviewed · How we verify
Hib-TT
Hib-TT is a conjugate vaccine that combines Haemophilus influenzae type b (Hib) polysaccharide antigen with tetanus toxoid carrier protein to elicit protective immune responses against both Hib infection and tetanus.
Hib-TT is a conjugate vaccine that combines Haemophilus influenzae type b (Hib) polysaccharide antigen with tetanus toxoid carrier protein to elicit protective immune responses against both Hib infection and tetanus. Used for Prevention of invasive Haemophilus influenzae type b disease in infants and children, Prevention of tetanus.
At a glance
| Generic name | Hib-TT |
|---|---|
| Also known as | Hib conjugate |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Drug class | Conjugate vaccine |
| Target | Haemophilus influenzae type b capsular polysaccharide; tetanus toxoid |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine works by conjugating the Hib capsular polysaccharide to tetanus toxoid, which enhances immunogenicity and promotes T-cell dependent B-cell responses. This conjugation strategy improves the immune response compared to polysaccharide-only vaccines, particularly in young children, and provides dual protection against Haemophilus influenzae type b invasive disease and tetanus toxin.
Approved indications
- Prevention of invasive Haemophilus influenzae type b disease in infants and children
- Prevention of tetanus
Common side effects
- Local injection site reactions (erythema, swelling, pain)
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Exploratory Clinical Study of MT-2301 (PHASE2)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Phase 3 Study of BK1310 in Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |